Cizzle Bio’s South Texas laboratory deal widens CIZ1B reach, but the real test starts now
Cizzle Bio’s BioBridge Global collaboration widens CIZ1B access in South Texas, but validation, reimbursement and evidence remain decisive.
Medical Devices & Diagnostics
Pharma & Biotech
Can Thyora Therapeutics turn a strained four-carbon ring into safer covalent cancer drugs?
Thyora Therapeutics launches a Science-backed covalent drug platform, but its first candidate and clinical development timeline remain undisclosed.
Medical Devices & Diagnostics
Cizzle Bio launches CIZ1B lung cancer blood test in limited Texas commercial rollout
Cizzle Bio launches CIZ1B in Texas as a lung cancer blood test, with wider adoption hinging on clinical validation and reimbursement.
Pharma & Biotech
Can Anixa’s breast cancer vaccine and lira-cel CAR-T therapy translate early immune signals into clinical benefit?
Anixa Biosciences has presented completed Phase 1 data for its alpha-lactalbumin breast cancer vaccine and updated survival observations for liraltagene autoleucel in recurrent ovarian cancer. The findings strengthen the biological rationale behind both programmes, but controlled efficacy evidence, biomarker clarity and successful dose optimisation remain essential before either platform can be considered clinically validated.